PENETREX Drug Patent Profile

Which patents cover Penetrex, and when can generic versions of Penetrex launch?

Penetrex is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in PENETREX is enoxacin. There are three drug master file entries for this compound. Additional details are available on the enoxacin profile page.

Summary for PENETREX

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PENETREX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-004	Dec 31, 1991		DISCN	No	No
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-005	Dec 31, 1991		DISCN	No	No

International Patents for PENETREX

See the table below for patents covering PENETREX around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	227529	UN PROCEDIMIENTO PARA PREPARAR UN DERIVADO DE ACIDOS 6-HALOGENO-4-OXO-7-(1-PIPERAZINIL)-1,8-NAFTIRIDIN-CARBOXILICOS
Poland	120155
Germany	3266261

Supplementary Protection Certificates for PENETREX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2344130	2017C/031	Belgium		PRODUCT NAME: OZENOXACINE; AUTHORISATION NUMBER AND DATE: BE509591 20170519
2344130	122017000073	Germany		PRODUCT NAME: OZENOXACIN; NAT. REGISTRATION NO/DATE: 97303.00.00 20170803; FIRST REGISTRATION: BELGIEN BE509591 20170517
2344130	C201730036	Spain		PRODUCT NAME: OZENOXACINO; NATIONAL AUTHORISATION NUMBER: 82357-ES/H/0414/001/DC; DATE OF AUTHORISATION: 20170830; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): ES/H/414/01/DC; DATE OF FIRST AUTHORISATION IN EEA: 20170519

Investment Scenario and Fundamentals Analysis for Penetrex

Last updated: February 23, 2026

What is Penetrex?

Penetrex is a topical cream marketed for the treatment of nerve pain, inflammation, and musculoskeletal conditions. It contains multiple active ingredients, including baclofen, methyl salicylate, and other compounds intended to reduce pain and inflammation. The product is marketed primarily in the United States and available through online and retail channels. It is not classified as a prescription medication but is sold as an over-the-counter (OTC) supplement or topical analgesic.

Does Penetrex have regulatory approval?

Penetrex is not approved by the U.S. Food and Drug Administration (FDA) as a drug; rather, it is classified as a dietary supplement or topical analgesic, depending on jurisdiction. Its ingredients, such as methyl salicylate, are generally recognized as safe (GRAS) when used appropriately. However, the lack of FDA approval limits its market exclusivity and regulatory protections, making its positioning more vulnerable to competitors and regulatory scrutiny.

What are the market fundamentals?

Market size and growth prospects

The global topical pain relief market was valued at approximately USD 6.5 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of around 5% through 2030, driven by aging populations, increasing prevalence of musculoskeletal conditions, and preference for non-invasive treatments.

Competitive landscape

Penetrex competes with a broad array of OTC topical analgesics, including products like Biofreeze, Icy Hot, Aspercreme, and prescription options such as NSAID patches and creams. Many players leverage FDA-approved ingredients, which influence consumer confidence and regulatory barriers.

Distribution channels

The product is sold via online channels (such as Amazon), health food stores, and independent pharmacies. E-commerce accounts for nearly 50% of the OTC topical pain relief market, enabling rapid scale-up but also intensifying direct competition.

Regulatory risk

The lack of formal FDA approval increases regulatory risk. While OTC products are generally less restrictive, any claims of exceeding common analgesic benefits or reclassification as a drug could trigger FDA review and potential restrictions.

What is the product's fundamental strength?

Ingredient profile

Penetrex uses a combination of active ingredients, notably methyl salicylate (a counterirritant), arnica, and vitamin B6. The formulation claims to offer deep tissue pain relief without the systemic side effects of oral medications.

Intellectual property and branding

The product has existing branding and consumer recognition but lacks patents specific to its formulation. This limits protection against generic or similar products entering the market.

Clinical evidence

Clinical studies backing Penetrex's efficacy are limited. The product relies largely on consumer testimonials and anecdotal evidence, contrasting with competitors that have published peer-reviewed clinical trials.

Regulatory and legal considerations

Without FDA approval or a drug license, Penetrex operates in a largely unregulated environment. This reduces costs but increases vulnerability to regulatory actions and legal liabilities, especially if claims are deemed misleading.

What are the risks for investors?

• Regulatory risk: Changes in regulation or adverse rulings could restrict sales or require reformulation.
• Market penetration: Differentiation from competitors relies on branding rather than clinical validation, risking obsolescence.
• Patent and IP issues: Lack of patent protection exposes the product to imitation, reducing profit margins.
• Efficacy claims: Reliance on anecdotal evidence limits scientific credibility, affecting consumer trust and repeat sales.

What are potential growth strategies?

• Pursuing clinical trials: Demonstrating efficacy through peer-reviewed studies could support claims and expand to prescription markets.
• Regulatory registration: Achieving FDA approval or supplement notification could enhance credibility and enable stronger marketing claims.
• Market expansion: Entering international markets with similar OTC regulations and increasing online presence can grow sales.
• Product reformulation: Developing proprietary formulations or delivery mechanisms could provide patent protection and differentiation.

Financial outlook considerations

Specific financial data for Penetrex are unavailable publicly, as it is a privately distributed OTC product. Investors should consider the broader topical analgesic market's growth, competitive pressures, and regulatory environment to assess potential profitability.

Key Takeaways

• Penetrex operates in the OTC topical pain relief segment with limited clinical validation.
• Regulatory status remains informal; FDA approval could significantly alter its market positioning.
• The global topical pain relief market grows steadily, driven by demographics and consumer preference for non-invasive options.
• Competition is intense, mainly from well-established brands with FDA-approved ingredients.
• Growth relies on clinical validation, regulatory clearance, and strategic marketing initiatives.

FAQs

1. Is Penetrex FDA-approved?
No, Penetrex is marketed as an OTC supplement or topical analgesic without FDA approval as a drug.

2. Can Penetrex replace prescription pain medications?
It is marketed for mild to moderate pain but does not have clinical validation comparable to prescription drugs.

3. What are the competitive advantages of Penetrex?
Its non-prescription status and proprietary blend appeal to consumers seeking OTC solutions, though it lacks patent protection and peer-reviewed evidence.

4. How vulnerable is Penetrex to regulatory action?
The absence of FDA approval means it operates in a less regulated environment but is susceptible to future regulatory scrutiny or claims.

5. What are the prospects for market growth?
The OTC topical pain relief market is expanding, but Penetrex’s growth depends on product differentiation, clinical validation, and regulatory navigation.

---

References

1. Statista. (2022). Global topical pain relief market size. https://www.statista.com/
2. U.S. Food and Drug Administration. (2020). OTC drug review and regulation. https://www.fda.gov/
3. MarketWatch. (2021). Topical pain relief market forecast. https://www.marketwatch.com/
4. FDA. (2019). Guidance for Industry: Nonprescription Drugs Advisory Committee. https://www.fda.gov/